1. Scrip

Leo Pharma Picks Up Momentum As Growth Plan Progresses

 
• By Jessica Merrill

CEO Christophe Bourdon talked to Scrip about the company’s revitalization as revenue grew 10% in the third quarter.

(Shutterstock)

Leo Pharma’s turnaround plan has taken root and the company is now in a growth phase on the back of launches like Adbry/Adtralza (tralokinumab) for atopic dermatitis and Anzupgo (delgocitinib) for chronic hand eczema, while earnings have also improved after a cost-cutting initiative.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Interviews

More from Business

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

Europe Pharma Heavyweights Call For Higher Drug Prices At Home

 
• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.